On September 17, 2026, Halozyme Therapeutics priced a $1.3 billion private offering of convertible senior notes due 2033 with a 1.50% coupon and an initial conversion price of approximately $139.84 per share. The company granted purchasers a 13-day option to buy up to an additional $200 million in notes. Net proceeds are estimated at $1.275 billion, or $1.471 billion if the option is exercised. Halozyme intends to use approximately $652.5 million of these proceeds to repurchase its outstanding 2027 and 2028 convertible notes concurrently with the pricing. The remaining funds will support general corporate purposes, including capped call transactions costing roughly $162.5 million. Halozyme Therapeutics is a biopharmaceutical company specializing in subcutaneous drug delivery technologies.
